Jeffrey Wallin - Senior Scientist, Oncology Biomarker Development

Jeffrey Wallin

Senior Scientist, Oncology Biomarker Development

"The ability to have a potential positive effect on the lives of cancer patients is what inspires me. At Genentech I feel fortunate to have the opportunity to contribute to the development of potential drugs for the treatment of these patients."
Years at Genentech

I have really enjoyed working at Genentech. The opportunity to work with very talented colleagues and the company's record of taking novel approaches to drug discovery and development has been an amazing experience. While at Genentech, I’ve had the opportunity to work in both Research and Development. This has led to personal and team-oriented discoveries in the lab and the ability to work with outstanding clinical teams that rely on a deep understanding of biology to guide decision-making during clinical development.

Featured Publication

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Nat Commun. 2016 Aug 30;7:12624.

Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF.